– In a prospective, phase IV open‑label study in China, topical cenegermin produced corneal healing in 22/26 (84.6%, 95% CI 65.1–95.6%) patients with stage 2–3 neurotrophic keratopathy (NK) at 8 weeks.
– Treatment effects were durable through 56 weeks for most patients: 20/22 (90.9%) patients who achieved initial healing remained healed at week 56, while three experienced recurrence during follow‑up.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
